Sanofi Consumer Healthcare India Ltd (SANOFICONR) — shareholding pattern, promoter holding, financials and share price
About Sanofi Consumer Healthcare India Ltd (SANOFICONR)
Sanofi Consumer Healthcare India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SANOFICONR and on the BSE under scrip code 544250. Its ISIN is INE0UOS01011.
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. [1] It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
Sanofi Consumer Healthcare India Limited focuses on the consumer healthcare segment after being demerged from Sanofi India Limited.
The demerger was implemented as part of a Scheme of Arrangement, effective from June 1, 2024, marking a new phase for the company.
Listed peers in Pharmaceuticals: Viyash Scientific Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd, Blue Jet Healthcare Ltd, Strides Pharma Science Ltd, Sudeep Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹4,572.9 a share on 10 Jul 2026, Sanofi Consumer Healthcare India Ltd (SANOFICONR) was valued at a price-to-earnings ratio of 40.84x against an industry P/E of 36.41x and a price-to-book of 27.43x on a book value of ₹166.73 per share as of Dec 2025. Solomo computes return on equity of 67.16% and return on capital employed of 84.71% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 40.84x
- Industry P/E
- 36.41x
- P/B
- 27.43x
- EPS (TTM)
- ₹111.98
- Book value / share
- ₹166.73
- ROE
- 67.16%
- ROCE
- 84.71%
- ROA
- 47.15%
- Debt / equity
- 0.06x
- Dividend yield
- 1.64%
- EBITDA margin
- 38.42%
- 52-week range
- ₹3,950.5 – ₹5,493.1
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Dec 2025In the year ended Dec 2025, Sanofi Consumer Healthcare India Ltd (SANOFICONR) reported revenue of ₹878 crore, net profit of ₹240 crore and earnings per share of ₹104.25. That compares with revenue of ₹878 crore and net profit of ₹240 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹229 crore and net profit ₹68 crore (standalone).
| Metric | Dec 2023 8m | Dec 2023 | Dec 2024 | Mar 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 555 | 0 | 724 | 878 | 878 |
| Net profit (₹ cr) | 165 | -0.3 | 181 | 240 | 240 |
| EPS (₹) | - | - | 78.59 | 104.25 | 104.25 |
| Measure | 1Y |
|---|---|
| Sales growth | 21.24% |
| Profit growth | 32.65% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.27% of Sanofi Consumer Healthcare India Ltd (SANOFICONR) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.6% and domestic institutional investors (DII) hold 17.86%. Market capitalisation was ₹10,532 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Jun 2026: Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund 5.21%, Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Large Cap Fund 3.03%, Hdfc Life Insurance Company Limited 2.12%, Icici Prudential Smallcap Fund 1.57%, Sbi Dividend Yield Fund 1.47%, General Insurance Corporation Of India 1.3%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.27% | - | 2.6% | 17.86% | 28.73% |
| Mar 2026 | 71.27% | - | 2.76% | 17.57% | 28.73% |
| Dec 2025 | 71.27% | - | 2.83% | 17.33% | 28.73% |
| Sep 2025 | 71.27% | - | 2.94% | 17.21% | 28.73% |
| Jun 2025 | 71.27% | - | 3.24% | 16.89% | 28.73% |
| Mar 2025 | 60.4% | - | 4.53% | 25.48% | 39.6% |
| Dec 2024 | 60.4% | - | 4.42% | 25.35% | 39.6% |
| Sep 2024 | 60.4% | - | 5.22% | 24.03% | 39.6% |